Previous Article | Next Article ![]()
Infection and Immunity, February 2001, p. 1151-1159, Vol. 69, No. 2
Departments of Clinical
Immunology1 and
Rheumatology,2 Göteborg
University, S-41346 Göteborg, Sweden
Received 8 September 2000/Returned for modification 19 October
2000/Accepted 7 November 2000
Aluminum adjuvants are widely used in human vaccines based on their
ability to enhance antibody production. However, the mechanisms underlying these effects remain unknown. In the present study we
assessed the direct in vitro effect of aluminum hydroxide on human
peripheral blood monocytes, specifically with regard to its impact on
the phenotype and functional properties of this cell population. Our
results revealed significant changes in the accessory properties of
monocytes following short-term exposure of cultured cells to aluminum
hydroxide. Thus, flow cytometry analyses showed an increase in the
expression of major histocompatibility complex (MHC) class II, CD40,
CD54, CD58, CD83, and CD86 molecules on the monocytes. In addition,
many cells in the cultures containing aluminum hydroxide acquired
typical dendritic morphology. Increased synthesis of interleukin-4
(IL-4) mRNA, but not gamma interferon mRNA, was also
noted after exposure to aluminum hydroxide. The increase in cell
surface expression of MHC class II did not occur in the presence of
neutralizing IL-4 antibody or in cultures of highly purified
monocytes or CD4-depleted mononuclear cells. Our findings suggest that
aluminum hydroxide directly stimulates monocytes to produce
proinflammatory cytokines activating T cells. Activated Th2 cells
release IL-4, which in turn can induce an increase in the expression of
MHC class II molecules on monocytes. The increase in the expression of
antigen-presenting and costimulatory molecules leads to enhanced
accessory functions of monocytes. These properties of aluminum
hydroxide observed in vitro may explain its potent in vivo adjuvant effect.
Aluminum compounds have been widely
used as human vaccine adjuvants for more than 70 years. It is known
that their immunoadjuvant effect is associated with the induction of
Th2 responses (3, 4, 16). However, the mechanisms
underlying this effect remain unknown. It is believed that aluminum
adjuvants form a "depot" at the site of injection from which
antigen is released slowly, leading to a prolonged exposure to
antigen-presenting cells and lymphocytes (25). It has also
been demonstrated that aluminum hydroxide enhances antigen uptake by
the antigen-presenting cells in vitro (26). Whether
aluminum adjuvants elicit any direct stimulatory effect on cells
involved in immune responses remains unknown. Aluminum compounds are
themselves not immunogenic, nor do they act as haptens
(29).
In the present study we investigated the direct effect of aluminum
hydroxide on human monocytes in in vitro cultures of peripheral blood
mononuclear cells (PBMC). Exposure to aluminum hydroxide led to a
significant activation of the accessory properties of monocytes.
Further experiments showed an involvement of interleukin-4 (IL-4) in
the increase of cell surface expression of major
histocompatibility complex (MHC) class II molecules induced by
aluminum hydroxide. These findings indicate that aluminum hydroxide can
directly stimulate antigen-presenting cells, which may represent an
important mechanism underlying its in vivo immunoadjuvant effect.
Cell preparation and culture conditions.
PBMC were separated
from heparinized whole blood on a Lymphoprep density gradient (Nycomed
Pharma AS, Oslo, Norway), washed, and resuspended in complete medium
(RPMI 1640 medium containing 1% L-glutamine (Gibco,
Glasgow, Scotland) supplemented with 1% nonessential amino acids
(Gibco), 1% sodium pyruvate (Gibco), 5 × 10
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.2.1151-1159.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
The Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates
Accessory Properties of Human Monocytes via an
Interleukin-4-Dependent Mechanism
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
5 M
-mercaptoethanol, and 50 µg of
gentamicin sulfate (Schering-Plough, Stockholm, Sweden) per ml. The
complete RPMI was supplemented with fetal calf serum (Gibco catalog no.
10084-168) (RPMI-FCS). The endotoxin content of culture medium was
below 1 pg/ml, as determined by the Limulus assay.
) (R&D Systems) or an isotype-matched control (mouse
IgG2a; Sigma, St. Louis, Mo.) was added to the culture at a
concentration of 10 µg/ml. After 48 h of culture, all the cells
were harvested by gentle scraping with a rubber policeman, washed,
counted, and stained with monoclonal antibodies for flow cytometry analysis.
Culturing of human monocytic cell lines THP-1 and Mono Mac 6 was
performed in 10-ml culture flasks (Nunclon) as previously described
(39, 48). For stimulation with
Al(OH)3, cells from a 48-h culture were
harvested, washed, and recultured in six-well plates at a concentration
of 106 cells/ml in RPMI-10% FCS for 48 h
with or without 5 µg of Al(OH)3/ml. In some
experiments, THP-1 cells were first stimulated with human recombinant
IFN-
(100 U/ml; Boehringer Mannheim, Mannheim, Germany) in 10-ml
culture flasks for 24 h, harvested, washed, and recultured to
study the effect of Al(OH)3. After the incubation
all the cells were harvested, washed, counted, and analyzed by flow cytometry.
MAbs.
For direct immunostaining, mouse MAbs against the
following human antigens were used: HLA-DR, -DP, and -DQ
(fluorescein isothiocyanate [FITC] and phycoerythrin [PE]
conjugated) (CR3/43, IgG1
; Dako, Glostrup, Denmark), HLA-DR (PE
conjugated) (L243, IgG2a; Becton Dickinson, San Jose, Calif.), HLA-DP
(FITC conjugated) (HI43, IgG1
; PharMingen, San Diego, Calif.),
HLA-DQ (FITC conjugated) (SK10, IgG1; Becton Dickinson), HLA-A, -B, and
-C (FITC conjugated) (G46-2.6, IgG1
; PharMingen), CD3 (PE
conjugated) (LeuTM-4, IgG1
; Becton Dickinson), CD14 (PE conjugated)
(M
P9, IgG2b
; Becton Dickinson), CD19 (PE conjugated) (HD37, IgG1
; Dako), CD40 (FITC conjugated) (5C3, IgG1
; PharMingen), CD54
(PE conjugated) (LB-2, IgG2b; Becton Dickinson), CD58 (PE conjugated)
(L306.4, IgG2a; Becton Dickinson), CD83 (PE conjugated) (HB15A, IgG2b;
Immunotech, Marseille, France), CD86 (FITC conjugated) (BU63, IgG1;
Serotec, Oxford, United Kingdom).
Immunofluorescent staining and flow cytometry analysis. Cultured cells (2 × 105) were preincubated for 15 min at 4°C with human gamma globulin (Pharmacia and Upjohn, Uppsala, Sweden) at 500 µg/ml to block nonspecific Fc receptor-mediated binding of MAb and then with MAb directly conjugated to FITC or PE for 20 min at 4°C.
The corresponding isotype-matched controls were used for each sample (mouse IgG1-FITC and IgG2a-PE from Becton Dickinson and IgG2b-FITC and IgG2b-PE from PharMingen). For intracellular staining, cells were consecutively treated with FACS lysing solution and FACS permeabilizing solution (both from Becton Dickinson) prior to addition of either PE-conjugated CD68 MAb or IgG2b-PE (isotype control) according to the manufacturer's instructions. After two washing steps the cells were subjected to flow cytometry analysis by a FACSort (Becton Dickinson) using CELLQuest software (Becton Dickinson). Individual populations of cells were gated according to their forward- and side-scatter characteristics.Immunocytochemistry. For immunocytochemistry analyses, PBMC were cultured in two-well chamber slides (Nunc, Naperville, Ill.) at a concentration of 2 × 106 cells/ml in RPMI-10% FCS (1.5 ml/well) in a humidified atmosphere of 5% CO2 at 37°C. After 48 h of incubation the chambers were gently rinsed with warm PBS and air dried. The upper structure was removed, and the slides were fixed in ice-cold acetone (30 s in 50% acetone followed by 5 min in 100% acetone) and then air dried for 30 min. After this, endogenous peroxidase activity was blocked by incubation of the slides for 20 min at room temperature in a solution of 1 U of glucose oxidase (Sigma) per liter, 10 mM glucose, and 1 mM NaN3.
For immunostaining the slides were incubated overnight in a humid chamber at 4°C with purified mouse MAb to MHC class II (CR3/43, IgG1
; Dako) diluted 1:1,000 in PBS-Tween (0.05% Tween) containing 2%
BSA. Slides used as negative controls were incubated with an isotype-matched irrelevant MAb (mouse IgG1; Becton Dickinson).
After three 5-min washings with PBS, the slides were incubated for
1 h with a biotinylated F(ab')2
fragment of rabbit anti-mouse immunoglobulins (Dako) diluted 1:400 in
PBS-Tween-2% BSA-2% normal human serum. Thereafter, the slides were
incubated with avidin-conjugated peroxidase (ABC complex; Dako) for 30 min. The peroxidase deposition was revealed using substrate containing
amino-ethyl-carbazole (Sigma) and
H2O2, followed by a light
counterstaining with Mayer's hematoxylin.
Analysis of cytokine mRNA expression by reverse
transcription-PCR (RT-PCR).
Culturing of PBMC for mRNA
analysis was performed as described above, except that the cells were
harvested after 24 h of incubation either with or without aluminum
hydroxide (5 µg/ml) and washed, and the pellet was frozen at
137°C until further analysis.
, IL-1
, IL-10, tumor necrosis
factor alpha [TNF-
], and transforming growth factor beta
[TGF-
]) or 43 cycles (IL-2, IL-4, IL-5, IL-6, IFN-
, and GM-CSF)
of denaturation at 94°C for 45 s, annealing at 65°C for
45 s, and extension at 72°C for 2 min, followed by a final
extension for 7 min at 72°C.
Negative controls consisted of samples in which the reverse
transcriptase was omitted to verify the absence of contamination by
genomic DNA and a reagent control in which cDNA was replaced with
sterile distilled H2O.
The PCR products were tested by submarine electrophoretic separation
(GNA-200 gel electrophoresis apparatus; Pharmacia). Ten microliters of
sample mixed with 5 µl of gel loading solution (Sigma) was run on a
3% agarose gel (agarose MS-12, Pronadisa; Hispanlab, S.A.,
Madrid, Spain) containing ethidium bromide (Sigma) and in the presence
of the molecular size marker HaeIII-digested
X174
DNA (GIBCO).
Gel images were scanned (StudioScan II/si; Agfa), and densitometric
analysis (i.e., quantification of bands in terms of position, intensity, and area, referred to as volume analysis) was performed with IPLab Gel software for Macintosh (BioSystematica, Plymouth, United Kingdom). The results were expressed as a ratio calculated from
the "volume" of the amplified cytokine gene product divided by the
"volume" of the amplified G3PDH housekeeping gene product in the
same sample (densitometry units).
Statistical methods. Statistical evaluation of the data was performed using a paired nonparametric Wilcoxon signed-rank test. Differences were considered significant if the P value was below 0.05.
| |
RESULTS |
|---|
|
|
|---|
Aluminum hydroxide increased the cell surface expression of MHC class II, costimulatory, and adhesion molecules on monocytes. The direct effect of different concentrations of aluminum hydroxide gel on human PBMC was tested at different culture times. Our choice of concentrations was based on the awareness that concentrations of 3 mg/ml and higher were found to be toxic for macrophages in an in vivo model in guinea pigs (15) and that the usual dose of aluminum adjuvant for human vaccines is around 0.5 mg applied in 0.1 ml of saline (17).
Our preliminary experiments indicated, indeed, that concentrations of Al(OH)3 gel in culture medium of 400 µg/ml and higher were toxic (induced >30% dead cells after 48 h of culturing as detected by the trypan blue exclusion test). Therefore, we used concentrations of 1, 5, and 50 µg of Al(OH)3/ml and cultured thecells for 24, 48, and 72 h. Exposure of the PBMC to Al(OH)3 at 1, 5, and 50 µg/ml induced visible changes in light-scattering properties of the monocytes, as detected by flow cytometry analysis indicating augmentation of both size and granularity of the cells (Fig. 1 and data not shown). In contrast, the light-scattering properties of the cells in the lymphocyte gate remained unchanged during the experiments. The shift in the light-scattering properties of monocytes upon exposure to Al(OH)3 was comparable to that induced by a combination of GM-CSF and IL-4, the cytokines known as potent activators of monocytes and triggers of their maturation to dendritic cells.
|
-chain of all
products of the DP, DQ, and DR subregions. In contrast, the cell
expression of HLA-DQ and MHC class I molecules was not affected
by incubation with aluminum hydroxide (Fig.
2A).
|
|
Monocytes exposed to Al(OH)3 have a dendritic
appearance.
The results of the flow cytometry analyses indicated
that upon short exposure of cultured PBMC to
Al(OH)3, monocytes developed a phenotype which
was very similar to those described for cultured dendritic cells
undergoing the process of maturation (MHC class IIhigh, CD86high,
CD83+, and CD14
cells)
(34, 36, 46).
|
Aluminum hydroxide-triggered mRNA expression of
monocyte-derived and Th2 type cytokines.
To study the effect of
aluminum hydroxide on cytokine induction, we performed RT-PCR analysis
of mRNA gene expression for monocyte and T-cell cytokines. RT-PCR
analysis showed that exposure of PBMC to aluminum hydroxide induced an
increased expression of monocyte-derived cytokines (IL-1
, IL-1
,
and TNF) and of Th2 type cytokines (IL-4 and IL-6) (Table
1). On the other hand, there was no
induction of the expression of Th1 type cytokines IFN-
, IL-2, and
GM-CSF. We could not see any significant increase in synthesis of
mRNA for IL-5, TGF-
, or IL-10 either (Table 1).
|
Aluminum hydroxide-induced increase in the expression of MHC class
II was abolished by neutralization of IL-4.
Cytokines known to
contribute to the cell surface expression of MHC class II on monocytes
are IFN-
, IL-4, and GM-CSF (6, 12, 13). As shown above,
an increase in synthesis of IL-4 mRNA, but not of IFN-
or GM-CSF
mRNA, was observed in cell cultures exposed to
Al(OH)3. To test participation of IL-4 in the
up-regulation of the expression of MHC class II molecules, a
neutralizing antibody specific for IL-4 was introduced into the culture
of PBMC. The presence of this antibody completely abolished the
aluminum hydroxide-induced increase in the expression of MHC class II
expression on monocytes (Table 2),
whereas the isotype-matched control antibody did not have any effect
(data not shown). In contrast, neutralizing MAb specific for IFN-
did not significantly alter the expression of MHC class II in cultures
of PBMC stimulated with Al(OH)3 (data not shown).
These data indicated that IL-4 was specifically involved in the
increase in cell surface expression of MHC class II induced by aluminum
hydroxide.
|
Aluminum hydroxide did not influence the expression of MHC class II molecules on highly purified monocytes or monocytic cell lines. To avoid the presence of IL-4-producing cells in the culture, we used either highly purified CD14+ cells (95 to 99% purity) or PBMC depleted of CD4+ cells (the level of CD4+ cells was less than 3% MNC) by applying a magnetic sorting technique. In both cases the effect of aluminum hydroxide on the expression of MHC class II molecules on monocytes was almost completely abolished (data not shown), indicating that T cells were the prerequisite for this phenomenon.
To further study the effects of aluminum hydroxide on pure monocyte populations, we used two monocytic cell lines representing different stages of differentiation. THP-1 is a human myelomonocytic cell line (39) which does not express MHC class II molecules unless induced to differentiate with, e.g., IFN-
treatment
(41). In contrast, Mono Mac 6 cells have phenotypic and
functional characteristics of mature blood monocytes expressing MHC
class II molecules and CD14 (48).
Despite their different characteristics, neither of these cell lines
was found to respond to the stimulation with aluminum hydroxide with
any increase in the MHC class II expression (data not shown). In
contrast, stimulation with IFN-
induced the MHC class II expression
on THP-1 cells.
| |
DISCUSSION |
|---|
|
|
|---|
In the present study we made an attempt to elucidate the mechanisms underlying the potent immunoadjuvant effect of aluminum hydroxide. The function of this major vaccine adjuvant for human use is still poorly understood. The original explanation of a "depot effect" proposed in the 1930s (14) was later challenged, when it was demonstrated that excision of the complex of antigen and aluminum gel from a subcutaneous injection site shortly after injection did not diminish the immune response (19). Other studies implicated that T-cell-dependent mechanisms were involved, at least in attracting eosinophils to the injection site (35, 43). It was hypothesized that particles of aluminum, which easily bind to proteins, can be covered by immunoglobulins in situ and then may activate mast cells through Fc receptors (8). The cross-linking of Fc receptors on mast cells would then induce production of Th2-type cytokines like IL-4 and IL-5 (33). However, this idea has never been experimentally proved.
In an attempt to elucidate the properties of aluminum adjuvants, we exposed isolated PBMC from normal individuals to aluminum hydroxide. We made an attempt to make the concentration of aluminum hydroxide in cell cultures close to the vaccine content (i.e., 5 mg/ml), but it had to be greatly reduced because of its toxic effect. In our experiments, aluminum hydroxide applied at a concentration of 5 µg/ml did not affect cell viability and rapidly stimulated antigen-presenting cells. However, the actual amount of aluminum hydroxide in regional lymph nodes, where interaction between antigen-presenting cells and T cells occurs, is unknown.
After 48 h of in vitro exposure of human PBMC to this adjuvant, a large increase in the monocytic expression of surface molecules implicated in antigen presentation and T-cell activation occurred. Cultured monocytes then acquired high cell surface expression of MHC class II and B7-2 (CD86) and became CD83+, which is considered characteristic of mature dendritic cells (5, 18, 46, 47). Also, an increase in the expression of the costimulatory and adhesion molecules ICAM-1 (CD54), LFA-3 (CD58), and CD40, as observed in our study, has been attributed to mature dendritic cells (7). In addition, monocytes stimulated with Al(OH)3 developed dendritic morphology, as revealed by immunocytochemistry analysis. The observed results were not due to an increased number of cells, since Al(OH)3 did not induce proliferative responses as estimated by [3H]thymidine incorporation (data not shown).
Usually the process of maturation of dendritic cells in the culture
requires 5 to 7 days of stimulation of monocytes by a combination of
GM-CSF and IL-4 followed by an additional 2 to 3 days of activation
with either proinflammatory cytokines like IL-1, TNF, and IFN-
or
lipopolysaccharide (37, 46). Such features of mature
dendritic cells were acquired by cultured monocytes after 48 h in
the presence of Al(OH)3.
Stimulation of PBMC with aluminum hydroxide induced an increase in
IL-1
, IL-1
, IL-6, and TNF mRNA expression. Above cytokines are typically produced by activated monocytes/macrophages and dendritic
cells (9, 42). Moreover, IL-1
, IL-1
and TNF are known to induce the maturation of dendritic cells (37). An
increased synthesis of certain Th2-type cytokine mRNAs, including
those for IL-4 and IL-6, was observed, which is of potential
significance in differentiation of B cells into antigen-specific
antibody-secreting cells. In contrast, typical Th1-type cytokines like
IL-2 and IFN-
were not induced by stimulation with aluminum
hydroxide. mRNA for GM-CSF, an important cytokine directing
maturation of dendritic cells (1, 37), was virtually
absent in our experiments. Hence, we observed the selectivity in the
aluminum hydroxide's effect on PBMC with respect to cytokine profile.
Importantly, mRNA for IL-4 was detected in all cell samples exposed to Al(OH)3. This cytokine can be produced in the cultures of PBMC by activated Th2, Th0, and NK T cells (27, 45) and is rapidly taken up by different types of cells expressing IL-4 receptors (22, 30). Therefore, detection of this cytokine in cell culture supernatants is often problematic. IL-4 is a pleiotropic cytokine involved in regulation of different immunological functions (28), in particular via inducing MHC class II expression on monocytes (38). It was previously demonstrated that IL-4 up-regulates the cellular expression of HLA-DR and HLA-DP but not HLA-DQ molecules (13). In our experiments we observed a significant increase of cellular expression of HLA-DR and HLA-DP, but not HLA-DQ, upon exposure to aluminum hydroxide, implying that this effect could be mediated by IL-4. The simultaneous decrease in the expression of a common monocyte marker, CD14, could be also due to IL-4, since this cytokine is known to down-regulate transcription of CD14 mRNA (24).
Other cytokines known to increase cellular expression of MHC class II
proteins on monocytes are IFN-
, IL-13, and GM-CSF (6, 10,
12). IFN-
is a potent activator of all the three HLA class II
gene products and of HLA class I products as well (11, 23). However, we found no significant increase of either HLA-DQ or MHC class I expression in our system. This finding together with the
lack of IFN-
mRNA induction indicated that this cytokine was not
involved in Al(OH)3-triggered up-regulation of
MHC class II. In addition, the presence of a MAb specific for IFN-
in the cultures exposed to Al(OH)3 did not
significantly influence the expression of MHC class II. GM-CSF induces
the expression of HLA-DR and -DP molecules as well as of CD1a, -b, and
-c (13, 21). Since the expression of CD1 molecules was not
affected by aluminum hydroxide (40), the participation of
this cytokine can also be ruled out. Neither was mRNA for GM-CSF
induced by aluminum hydroxide.
Our neutralization experiments provided direct evidence that IL-4 was
the major factor mediating the increase in the expression of MHC class
II molecules induced by aluminum hydroxide. In addition, cultures of
highly purified monocytes and CD4-depleted mononuclear cells did not
show increased expression of MHC class II upon exposure to
Al(OH)3. Experiments with the monocytic cell
lines THP-1 and Mono Mac 6 further supported the results obtained from
cultures of purified peripheral blood monocytes. Addition of human
recombinant IL-4 to the cultures did not influence the expression of
MHC class II molecules on THP-1 and Mono Mac 6 cells, although the same concentration of this cytokine induced their up-regulation on peripheral blood monocytes (data not shown). For interpretation of these results, however, it should be kept in mind that the studied
monocytic cell lines constitutively have low levels of the
chain of
the IL-4 receptor complex (31, 44), which may affect the
efficiency of signaling through the receptor.
Interestingly, in cultures of adherent cells the effect of aluminum hydroxide on the MHC class II expression was not diminished compared to the effect in whole PBMC, but rather more pronounced. The cultures of adherent cells, although enriched for monocytes, still contained a considerable portion of T cells (13 to 15% MNC). The remaining T cells could then produce a sufficient amount of IL-4 to induce higher expression of MHC class II molecules on monocytes in the culture.
Our results suggest that aluminum hydroxide primarily activates
monocytes to produce proinflammatory cytokines and to increase the
surface expression of costimulatory and adhesion molecules. Given the
well-known involvement of NF-
B in the regulation of the
transcription of IL-1
, IL-1
, IL-6, and TNF, as well as of B-7 and
ICAM-1 genes, we suggest that NF-
B could be directly activated by
aluminum hydroxide. In addition, we show that aluminum hydroxide
induces production of IL-4, which in turn increases the expression of
MHC class II on the antigen-presenting cells. Due to these changes, the
accessory cells become functionally more efficient in antigen
presentation, possibly representing the major mechanism of the in vivo
immunoadjuvant effect of aluminum hydroxide.
| |
ACKNOWLEDGMENTS |
|---|
We acknowledge Liliana Ceafalau for help with monocytic cell lines, Esbjörn Telemo for fruitful discussion, and Sergey Ulanov for statistical analysis of the data. The excellent technical assistance of Ingela Delgado and Florence Härling is gratefully acknowledged.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: Pulmonary Research Group, Room 574, HMRC, University of Alberta, Edmonton, Alberta, Canada T6G 2S2. Phone: (780) 492-1909. Fax: (780) 492-5329. E-mail: marina.ulanova{at}immuno.gu.se.
Editor: J. D. Clements
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Anderlini, P.,
D. Przepiorka,
R. Champlin, and M. Korbling.
1996.
Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals.
Blood
88:2819-2825 |
| 2. |
Artis, D.,
N. E. Humphreys,
A. J. Bancroft,
N. J. Rothwell,
C. S. Potten, and R. K. Grencis.
1999.
Tumor necrosis factor alpha is a critical component of interleukin 13-mediated protective T helper cell type 2 responses during helminth infection.
J. Exp. Med.
190:953-962 |
| 3. |
Brewer, J. M.,
M. Conacher,
C. A. Hunter,
M. Mohrs,
F. Brombacher, and J. Alexander.
1999.
Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling.
J. Immunol.
163:6448-6454 |
| 4. | Brewer, J. M., M. Conacher, A. Satoskar, H. Bluethmann, and J. Alexander. 1996. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur. J. Immunol. 26:2062-2066[Medline]. |
| 5. |
Caux, C.,
B. Vanbervliet,
C. Massacrier,
M. Azuma,
K. Okumura,
L. L. Lanier, and J. Banchereau.
1994.
B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
J. Exp. Med.
180:1841-1847 |
| 6. |
Chang, C. H.,
J. D. Fontes,
M. Peterlin, and R. A. Flavell.
1994.
Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes.
J. Exp. Med.
180:1367-1374 |
| 7. | Clark, G. J., and D. N. J. Hart. 1999. Phenotypic characterization of dendritic cells. In M. T. Lotze (ed.), Dendritic cells: biology and clinical applications. Academic Press, New York, N.Y. |
| 8. | Cooper, P. D. 1994. The selective induction of different immune responses by vaccine adjuvants, p. 126-158. In G. L. Ada (ed.), Strategies in vaccine design. R.G. Landes Company, Austin, Tex. |
| 9. |
de Saint-Vis, B.,
I. Fugier-Vivier,
C. Massacrier,
C. Gaillard,
B. Vanbervliet,
S. Ait-Yahia,
J. Banchereau,
Y. J. Liu,
S. Lebecque, and C. Caux.
1998.
The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation.
J. Immunol.
160:1666-1676 |
| 10. | de Waal Malefyt, R., C. G. Figdor, R. Huijbens, S. Mohan-Peterson, B. Bennett, J. Culpepper, W. Dang, G. Zurawski, and J. E. de Vries. 1993. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J. Immunol. 151:6370-6381[Abstract]. |
| 11. | Figueiredo, F., T. J. Koerner, and D. O. Adams. 1989. Molecular mechanisms regulating the expression of class II histocompatibility molecules on macrophages. Effects of inductive and suppressive signals on gene transcription. J. Immunol. 143:3781-3786[Abstract]. |
| 12. | Fischer, H. G., S. Frosch, K. Reske, and A. B. Reske-Kunz. 1988. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J. Immunol. 141:3882-3888[Abstract]. |
| 13. | Gerrard, T. L., D. R. Dyer, and H. S. Mostowski. 1990. IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. J. Immunol. 144:4670-4674[Abstract]. |
| 14. | Glenny, A. T., G. A. H. Buttle, and M. F. Stevens. 1931. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: toxoid precipitated with alum. J. Pathol. 34:267-275[CrossRef]. |
| 15. | Goto, N., H. Kato, J. Maeyama, M. Shibano, T. Saito, J. Yamaguchi, and S. Yoshihara. 1997. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15:1364-1371[CrossRef][Medline]. |
| 16. | Grun, J. L., and P. H. Maurer. 1989. Different T helper cell subsets elicited in mice utilising two different adjuvant vehicles: the role of endogenous IL-1 in proliferative responses. Cell. Immunol. 121:134-145[CrossRef][Medline]. |
| 17. | Gupta, R. K., B. E. Rost, E. Relyveld, and G. R. Siber. 1995. Adjuvant properties of aluminium and calcium compounds, p. 229-248. In M. F. Powell, and M. J. Newman (ed.), Vaccine design: the subunit and adjuvant approach. Plenum Press, New York, N.Y. |
| 18. |
Hart, D. N. J.
1997.
Dendritic cells: unique leucocyte populations which control the primary immune response.
Blood
90:3245-3287 |
| 19. | Holt, L. B. 1950. Developments in diphtheria prophylaxis. Heinemann, London, United Kingdom. |
| 20. | Joseph, S. B., K. T. Miner, and M. Croft. 1998. Augmentation of naive, Th1 and Th2 effector CD4 responses by IL-6, IL-1 and TNF. Eur. J. Immunol. 28:277-289[CrossRef][Medline]. |
| 21. | Kasinrerk, W., T. Baumruker, O. Majdic, W. Knapp, and H. Stockinger. 1993. CD1 molecule expression on human monocytes induced by granulocyte-macrophage colony-stimulating factor. J. Immunol. 150:579-584[Abstract]. |
| 22. | Kelleher, P., A. Maroof, and S. C. Knight. 1999. Retrovirally induced switch from production of IL-12 to IL-4 in dendritic cells. Eur. J. Immunol. 29:2309-2318[CrossRef][Medline]. |
| 23. | King, D. P., and P. P. Jones. 1983. Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. J. Immunol. 131:315-318[Abstract]. |
| 24. | Lauener, R. P., S. M. Goyert, R. S. Geha, and D. Vercelli. 1990. Interleukin 4 down-regulates the expression of CD14 in normal human monocytes. Eur. J. Immunol. 20:2375-2381[Medline]. |
| 25. | Lindblad, E. B. 1995. Aluminium adjuvants, p. 21-35. In D. E. S. Stewart-Tull (ed.), The theory and practical application of adjuvants. John Wiley & Sons Ltd, New York, N.Y. |
| 26. | Mannhalter, J. W., H. O. Neychev, G. J. Zlabinger, R. Ahmad, and M. M. Eibl. 1985. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. 61:143-151[Medline]. |
| 27. | Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173[CrossRef][Medline]. |
| 28. | Nelms, K., A. D. Keegan, J. Zamorano, J. J. Ryan, and W. E. Paul. 1999. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17:701-738[CrossRef][Medline]. |
| 29. | Nicklas, W. 1992. Aluminum salts. Res. Immunol. 143:489-494[CrossRef][Medline]. |
| 30. |
Ohara, J., and W. E. Paul.
1988.
Up-regulation of interleukin 4/B-cell stimulatory factor 1 receptor expression.
Proc. Natl. Acad. Sci. USA
85:8221-8225 |
| 31. | Quentmeier, H., K. Kolsdorf, M. Zaborski, and H. G. Drexler. 1995. IL-4R alpha and gamma chain expression in LPS- and IL-4-stimulated MONO-MAC-6 cells. Leukemia 9:336-340[Medline]. |
| 32. |
Rincon, M.,
J. Anguita,
T. Nakamura,
E. Fikrig, and R. A. Flavell.
1997.
Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells.
J. Exp. Med.
185:461-469 |
| 33. | Romagnani, S. 1992. Induction of TH1 and TH2 responses: a key role for the `natural' immune response? Immunol. Today 13:379-381[CrossRef][Medline]. |
| 34. | Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196:137-151[CrossRef][Medline]. |
| 35. | Sakata, K., K. Tashiro, M. Hirashima, and H. Hayashi. 1985. Selective regulation of chemotactic lymphokine production. I. Selective potentiation of eosinophil chemotactic lymphokine production in alum hydroxy gel- and Bordetella pertussis vaccine-treated guinea pigs. J. Immunol. 135:3463-3467[Abstract]. |
| 36. |
Sallusto, F.,
M. Cella,
C. Danieli, and A. Lanzavecchia.
1995.
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
J. Exp. Med.
182:389-400 |
| 37. |
Sallusto, F., and A. Lanzavecchia.
1994.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
J. Exp. Med.
179:1109-1118 |
| 38. | te Velde, A. A., J. P. Klomp, B. A. Yard, J. E. de Vries, and C. G. Figdor. 1988. Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J. Immunol. 140:1548-1554[Abstract]. |
| 39. | Tsuchiya, S., S. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. Tada. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26:171-176[Medline]. |
| 40. | Ulanova, M., A. Tarkowski, S. Porcelli, and L. Hanson. 2000. Antigen-specific regulation of CD1 expression in humans. J. Clin. Immunol. 20:203-211[CrossRef][Medline]. |
| 41. | Vey, E., J. H. Zhang, and J. M. Dayer. 1992. IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J. Immunol. 149:2040-2046[Abstract]. |
| 42. | Vignola, A. M., M. Gjomarkaj, B. Arnoux, and J. Bousquet. 1998. Monocytes. J. Allergy Clin. Immunol. 101:149-152[CrossRef][Medline]. |
| 43. | Walls, R. S. 1977. Eosinophil response to alum adjuvants: involvement of T cells in non-antigen dependent mechanisms. Proc. Soc. Exp. Biol. Med. 156:431-435[Medline]. |
| 44. | Yanai, H., T. Yoshino, K. Takahashi, Y. Ninomiya, and T. Akagi. 1996. Regulation of interleukin-2 receptor gamma chain mRNA expression in human monocytic cell line THP-1. Acta Med. Okayama 50:145-150. |
| 45. |
Yoshimoto, T., and W. E. Paul.
1994.
CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3.
J. Exp. Med.
179:1285-1295 |
| 46. |
Zhou, L. J., and T. F. Tedder.
1996.
CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.
Proc. Natl. Acad. Sci. USA
93:2588-2592 |
| 47. | Zhou, L. J., and T. F. Tedder. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154:3821-3835[Abstract]. |
| 48. | Ziegler-Heitbrock, H. W., E. Thiel, A. Futterer, V. Herzog, A. Wirtz, and G. Riethmuller. 1988. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer 41:456-461[Medline]. |
| 49. |
Zitvogel, L.,
J. I. Mayordomo,
T. Tjandrawan,
A. B. DeLeo,
M. R. Clarke,
M. T. Lotze, and W. J. Storkus.
1996.
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
J. Exp. Med.
183:87-97 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|